25/01/2008 (Agence Europe) - On Thursday 24 January, the European Medicines Agency recommended the approval of thalidomide for the treatment of multiple myeloma, a rare cancer of the bone marrow. The product, in combination with an acylating agent (melphalan) can extend survival time by about 18 months in newly diagnosed multiple myeloma patients over 65 years of age. The Agency, however, issued several warnings because the product has a high toxicity level and is teratgenic. It must not,...